Rubio I G S, Silva M N C, Knobel M, Romão R, Possato R, Gebrin E M M S, Buchpiguel C, Medeiros-Neto G
Thyroid Unit (LIM-25), Division of Endocrinology, Department of Medicine, University of São Paulo Medical School, São Paulo, Brazil.
J Endocrinol Invest. 2007 Jul-Aug;30(7):535-40. doi: 10.1007/BF03346345.
We investigated the effect of therapeutic doses of radioiodine (RAI) on peripheral serum messenger thyroglobulin RNA (Tg mRNA) and serum thyroglobulin (sTg) in patients with multinodular goiter (MNG) preceded or not by treatment with recombinant human TSH (rhTSH). Fourteen patients with large MNG (91-542 ml) received RAI (550-2960 MBq). Half of the patients received 0.45 mg of rhTSH prior to the treatment (RAI+rhTSH group) and half did not (RAI group). Patients' blood samples were collected before and 24, 48, and 72 h; 7 and 30 days; and 6, 9, and 12 months after RAI treatment. Serum Tg was measured by immunoradiometric assay, serum anti-Tg by radioimmunoassay, and quantification of circulating Tg mRNA was performed by real-time PCR. The shrinkage of MNG volume was documented by serial computed tomography (CT) scans before, 6 and 12 months after RAI. Peak Tg mRNA and sTg were reached earlier in the RAI+rhTSH group (24 h and 48 h) than in the RAI group (7 days). Both declined after the peak and the lowest levels were observed at 12 months. The mean reduction of the thyroid volume was 19.8% (RAI group) and 30.3% (RAI+rhTSH group) at 6 months (ns) and 32.8% RAI and 52.5% (RAI+rhTSH group) at 12 months (p<0.05). After RAI treatment there was a significant and positive correlation between goiter volume and sTg only in the RAI group (r=0.7; p=0.032). Serum anti-Tg had a transitory and relatively small elevation in 3 and 2 patients, respectively, in the RAI and RAI+rhTSH groups. We concluded that after RAI ablation of MNG there is a rapid release of Tg into the serum possibly from the colloid, which is followed by an elevation of serum Tg mRNA that may be due to an increased release of follicular cells into the blood stream. Both phenomena are enhanced by the use of rhTSH before RAI treatment as a consequence of a more effective and prolonged radiation exposure of the thyroid follicles.
我们研究了治疗剂量的放射性碘(RAI)对多结节性甲状腺肿(MNG)患者外周血清信使甲状腺球蛋白RNA(Tg mRNA)和血清甲状腺球蛋白(sTg)的影响,这些患者在接受RAI治疗之前是否接受过重组人促甲状腺素(rhTSH)治疗。14例患有大体积MNG(91 - 542 ml)的患者接受了RAI(550 - 2960 MBq)治疗。一半患者在治疗前接受0.45 mg的rhTSH(RAI + rhTSH组),另一半未接受(RAI组)。在RAI治疗前、治疗后24、48和72小时;7天和30天;以及6、9和12个月采集患者血样。通过免疫放射分析测定血清Tg,通过放射免疫分析测定血清抗Tg,并通过实时PCR对循环Tg mRNA进行定量。通过连续计算机断层扫描(CT)在RAI治疗前、治疗后6个月和12个月记录MNG体积的缩小情况。RAI + rhTSH组(24小时和48小时)的Tg mRNA和sTg峰值出现时间早于RAI组(7天)。两者在峰值后均下降,在12个月时观察到最低水平。6个月时,甲状腺体积的平均缩小率在RAI组为19.8%,在RAI + rhTSH组为30.3%(无显著差异),12个月时,RAI组为32.8%,RAI + rhTSH组为52.5%(p < 0.05)。RAI治疗后,仅在RAI组中,甲状腺肿体积与sTg之间存在显著正相关(r = 0.7;p = 0.032)。在RAI组和RAI + rhTSH组中,分别有3例和2例患者的血清抗Tg出现短暂且相对较小的升高。我们得出结论,RAI消融MNG后,Tg可能从胶体中快速释放到血清中,随后血清Tg mRNA升高,这可能是由于滤泡细胞向血流中的释放增加所致。由于甲状腺滤泡更有效且持续时间更长的辐射暴露,在RAI治疗前使用rhTSH会增强这两种现象。